Literature DB >> 29383637

Biomarkers in cancer therapy related cardiac dysfunction (CTRCD).

Rohit Moudgil1, Parag A Parekh2.   

Abstract

Biomarkers are at the cornerstone of preventive measures and contribute to the screening process. More recently, biomarkers have been used to gauge the biological response to the employed therapies. Since it is ubiquitously used to detect subclinical disease process, biomarkers also have found its place in cancer therapy related cardiac dysfunction (CTRCD). The aim of this review is to comprehensively present up-to-date knowledge of biomarkers in CTRCD and highlight some of the future biomedical technologies that may strengthen the screening process, and/or provide new insight in pathological mechanisms behind CTRCD.

Entities:  

Keywords:  Biomarkers; Cancer therapy related cardiac dysfunction (CTRCD); Heart failure

Mesh：

Substances：

Year:  2018        PMID： 29383637     DOI： 10.1007/s10741-018-9675-2

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN： 1382-4147            Impact factor:   4.214


  47 in total

1.  Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.

Authors:  M T Meinardi; D J van Veldhuisen; J A Gietema; W V Dolsma; F Boomsma; M P van den Berg; C Volkers; J Haaksma; E G de Vries; D T Sleijfer; W T van der Graaf
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Multiple biomarkers for risk prediction in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Wayne C Levy; Nancy K Sweitzer; James C Fang; Alan H B Wu; Lee R Goldberg; Mariell Jessup; Thomas P Cappola
Journal:  Circ Heart Fail       Date:  2012-02-23       Impact factor: 8.790

3.  The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.

Authors:  Nazanin Fallah-Rad; Jonathan R Walker; Anthony Wassef; Matthew Lytwyn; Sheena Bohonis; Tielan Fang; Ganhong Tian; Iain D C Kirkpatrick; Pawan K Singal; Marianne Krahn; Debjani Grenier; Davinder S Jassal
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

4.  Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?

Authors:  Vedat Köseoğlu; Semha Berberoğlu; Selmin Karademir; Erol Kismet; Neval Yurttutan; Erkan Demirkaya; Metin Sungur; Dursun Alehan
Journal:  Turk J Pediatr       Date:  2005 Jan-Mar       Impact factor: 0.552

5.  N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

Authors:  Maria T Sandri; Michela Salvatici; Daniela Cardinale; Laura Zorzino; Rita Passerini; Paola Lentati; Maria Leon; Maurizio Civelli; Giovanni Martinelli; Carlo M Cipolla
Journal:  Clin Chem       Date:  2005-06-02       Impact factor: 8.327

6.  Elevated B-type natriuretic peptide levels after anthracycline administration.

Authors:  T Suzuki; D Hayashi; T Yamazaki; T Mizuno; Y Kanda; I Komuro; M Kurabayashi; K Yamaoki; K Mitani; H Hirai; R Nagai; Y Yazaki
Journal:  Am Heart J       Date:  1998-08       Impact factor: 4.749

7.  Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.

Authors:  Debby Ngo; Sumita Sinha; Dongxiao Shen; Eric W Kuhn; Michelle J Keyes; Xu Shi; Mark D Benson; John F O'Sullivan; Hasmik Keshishian; Laurie A Farrell; Michael A Fifer; Ramachandran S Vasan; Marc S Sabatine; Martin G Larson; Steven A Carr; Thomas J Wang; Robert E Gerszten
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

8.  Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.

Authors:  Mauro Feola; Ornella Garrone; Marcella Occelli; Antonella Francini; Alberto Biggi; Gianluca Visconti; Fabrizia Albrile; Marco Bobbio; Marco Merlano
Journal:  Int J Cardiol       Date:  2009-11-27       Impact factor: 4.164

9.  Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.

Authors:  Paweł Stachowiak; Zdzisława Kornacewicz-Jach; Krzysztof Safranow
Journal:  Arch Med Sci       Date:  2013-04-30       Impact factor: 3.318

10.  Protein profiling reveals consequences of lifestyle choices on predicted biological aging.

Authors:  Stefan Enroth; Sofia Bosdotter Enroth; Åsa Johansson; Ulf Gyllensten
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.